The Cooper Companies, Inc. $COO Holdings Increased by Machina Capital S.A.S.

Machina Capital S.A.S. boosted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 247.4% during the third quarter, HoldingsChannel reports. The fund owned 39,164 shares of the medical device company’s stock after purchasing an additional 27,891 shares during the quarter. Machina Capital S.A.S.’s holdings in Cooper Companies were worth $2,214,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Keybank National Association OH increased its position in Cooper Companies by 59.6% during the 3rd quarter. Keybank National Association OH now owns 11,561 shares of the medical device company’s stock valued at $654,000 after purchasing an additional 4,319 shares during the period. New York Life Investment Management LLC increased its stake in Cooper Companies by 204.0% in the third quarter. New York Life Investment Management LLC now owns 81,502 shares of the medical device company’s stock valued at $4,607,000 after purchasing an additional 54,688 shares in the last quarter. AlphaCore Capital LLC increased its position in Cooper Companies by 1,371.1% in the 3rd quarter. AlphaCore Capital LLC now owns 65,421 shares of the medical device company’s stock valued at $3,698,000 after buying an additional 60,974 shares in the last quarter. Retirement Systems of Alabama increased its holdings in shares of Cooper Companies by 95.7% during the third quarter. Retirement Systems of Alabama now owns 80,210 shares of the medical device company’s stock valued at $4,534,000 after acquiring an additional 39,223 shares in the last quarter. Finally, Fulcrum Asset Management LLP bought a new stake in Cooper Companies during the 3rd quarter valued at $823,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cooper Companies news, Director Walter M. Rosebrough, Jr. purchased 3,000 shares of the company’s stock in a transaction dated Monday, September 14th. The stock was purchased at an average price of $54.29 per share, for a total transaction of $162,870.00. Following the transaction, the director owned 20,000 shares in the company, valued at $1,085,800. The trade was a 17.65% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lawrence Kurzius bought 10,000 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were bought at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the transaction, the director owned 31,099 shares of the company’s stock, valued at $1,708,268.07. The trade was a 47.40% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 34,701 shares of company stock worth $1,880,039 in the last three months. 2.08% of the stock is currently owned by corporate insiders.

Cooper Companies Stock Down 1.2%

Cooper Companies stock opened at $62.19 on Friday. The firm has a 50 day simple moving average of $58.65 and a 200 day simple moving average of $68.24. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83. The firm has a market capitalization of $11.83 billion, a price-to-earnings ratio of 21.23, a P/E/G ratio of 2.47 and a beta of 0.83.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the business posted $0.49 earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies declared that its board has initiated a share repurchase program on Wednesday, September 9th that permits the company to repurchase $3 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have commented on COO. Barclays raised Cooper Companies to a “hold” rating in a report on Wednesday, October 7th. Bank of America lowered Cooper Companies from a “buy” rating to a “neutral” rating and dropped their target price for the company from $80.00 to $65.00 in a report on Thursday, September 10th. Stifel Nicolaus set a $70.00 price target on shares of Cooper Companies and gave the company a “buy” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. cut their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Finally, Robert W. Baird set a $61.00 target price on shares of Cooper Companies and gave the company a “neutral” rating in a research note on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $68.60.

Cooper Companies Company Profile

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.